A practical reference on analytical methods: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-08 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
A frappé coffee, cold coffee, Greek frappé, or just frappé (Greek: φραπέ, frapé [fraˈpe]) is a Greek iced coffee drink generally made from spray-dried instant coffee, water, sugar, ice and milk. The word is often written frappe (without an accent). The frappé was invented in 1957 in Thessaloniki through experimentation by Dimitris Vakondios, a Nescafe representative. Greek Christos Lenzos (1930–2023), a coffeehouse (1964–2013) owner in Pangrati, has been recognized for his self-made version of Greek frappé coffee. Frappés are among the most popular forms of coffee in Greece and Cyprus and have become a hallmark of postwar outdoor Greek coffee culture.
In view of its widespread use, toxicity, and volatility, formaldehyde poses a significant danger to human health. In 2011, the US National Toxicology Program described formaldehyde as "known to be a human carcinogen".
Seeing her escape avenue, Owens agreed and vacuumed the house to indicate her acquiescence to becoming an extended member of the family. Later that day, Owens escaped from a launderette she and Rose had entered and returned home. Although initially too ashamed to divulge what had happened, when her mother noted the welts, bruises and exposed subcutaneous tissues on her daughter's body, Owens burst into tears and confided her ordeal. Owens' mother immediately reported her daughter's story to police, and the Wests were arrested and charged with assault, indecent assault, actual bodily harm and rape. The case was tried at Gloucester Magistrates Court on 12 January 1973, but by this date Owens had decided she could not face the ordeal of giving testimony. All charges pertaining to her ordeal were dropped, and the Wests agreed to plead guilty to the reduced charges of indecent assault and causing actual bodily harm. Rose and Fred were each fined £50 (equivalent to £1,000 in 2025) and the couple were allowed to walk free. When Owens heard this news, she attempted suicide.
=== Sources of toxicity === Diet – Liver is high in vitamin A. The liver of certain animals, including the polar bear, bearded seal, fish and walrus, are particularly toxic (see Liver (food) § Poisoning). It has been estimated that consumption of 500 grams (18 oz) of polar bear liver would result in an acute toxic dose for humans. Supplements – Dietary supplements can be toxic when taken above recommended dosages. Cod liver oil - According to the United States Department of Agriculture, a tablespoon (13.6 grams or 14.8 mL) of cod liver oil contains 4,080 μg of vitamin A. The tolerable upper intake level (UL) is 3000 μg/day for adults, 600 μg/day for children ages 1–3 years and 900 μg/day for children ages 4–8 years, so for all ages, but especially for young children, a tablespoon a day exceeds the UL.
Sources: en.wikipedia.org
A Pakistani newspaper, citing military sources, reported that seven TTP hideouts in Nangarhar, Paktika, and Khost provinces were destroyed and that more than 80 militants were killed; however, Taliban officials only reported airstrikes in the Nangarhar and Paktika provinces, adding that an airstrike in Bihsud District killed 18 civilians, including 11 children. Taliban officials condemned the airstrikes and warned of a calculated response at an appropriate time. Shayesteh Jan Ahadi, former head of the Paktia Provincial Council, stated that Pakistani airstrikes in several districts were very widespread and powerful. The United Nations Assistance Mission in Afghanistan (UNAMA) reported that Pakistan carried out airstrikes between 11:45 p.m. on 21 February and 12:15 a.m. on 22 February. UNAMA also reported that airstrikes in Paktika province damaged or destroyed infrastructure. On 23 February, UNAMA confirmed that over 13 civilians had been killed by the Pakistani airstrikes, with an additional seven injured. Pakistan described the operation as a retributive response to a series of suicide bombings inside Pakistan, including the 6 February bombing of a Shia mosque in Islamabad that killed 31 worshippers (claimed by ISIS–K), and attacks in Bajaur and Bannu districts in Khyber Pakhtunkhwa during the early days of Ramadan. Pakistan also claimed that the strikes were "intelligence-based, selective operations" against seven camps and hideouts belonging to the Tehreek-e-Taliban Pakistan (TTP), its affiliates, and the Islamic State – Khorasan Province (ISKP).
The urinary system consists of the two kidneys, two ureters, bladder, and urethra. It removes waste materials from the blood through urine, which carries a variety of waste molecules and excess ions and water out of the body. First, the kidneys filter the blood through their respective nephrons, removing waste products like urea, creatinine and maintaining the proper balance of electrolytes and turning the waste products into urine by combining them with water from the blood. The kidneys filter about 150 quarts (170 liters) of blood daily, but most of it is returned to the blood stream with only 1-2 quarts (1-2 liters) ending up as urine, which passes from the kidneys through the ureters into the bladder. The smooth muscles lining the ureter walls continuously tighten and relax through a process called peristalsis, forcing small amounts of urine into the bladder every 10–15 seconds. The bladder is a hollow balloon shaped organ located in the pelvis. It stores urine until the brain signals it to relax the urinary sphincter and release the urine into the urethra starting urination. A normal bladder can hold up to 16 ounces (half a liter) for 3–5 hours comfortably. Numerous diseases affect the urinary system including kidney stones, which are formed when materials in the urine concentrate enough to form a solid mass, urinary tract infections, which are infections of the urinary tract and can cause pain when urinating, frequent urination and even death if left untreated.
Protein kinases act on proteins, by phosphorylating them on their serine, threonine, tyrosine, or histidine residues. Phosphorylation can modify the function of a protein in many ways. It can increase or decrease a protein's activity, stabilize it or mark it for destruction, localize it within a specific cellular compartment, and it can initiate or disrupt its interaction with other proteins. The protein kinases make up the majority of all kinases and are widely studied. These kinases, in conjunction with phosphatases, play a major role in protein and enzyme regulation as well as signalling in the cell. A common point of confusion arises when thinking about the different ways a cell achieves biological regulation. There are countless examples of covalent modifications that cellular proteins can undergo; however, phosphorylation is one of the few reversible covalent modifications. This provided the rationale that phosphorylation of proteins is regulatory. The potential to regulate protein function is enormous given that there are many ways to covalently modify a protein in addition to regulation provided by allosteric control. In his Hopkins Memorial Lecture, Edwin Krebs asserted that allosteric control evolved to respond to signals arising from inside the cell, whereas phosphorylation evolved to respond to signals outside of the cell. This idea is consistent with the fact that phosphorylation of proteins occurs much more frequently in eukaryotic cells in comparison to prokaryotic cells because the more complex cell type evolved to respond to a wider array of signals.
Sources: en.wikipedia.org
Hahn was shot in the back in October 1951 by a disgruntled inventor who wished to highlight the neglect of his ideas by mainstream scientists. Hahn was injured in a motor vehicle accident in 1952, and had a minor heart attack the following year. In 1962, he published a book, Vom Radiothor zur Uranspaltung (lit. 'From Radiothorium to Uranium Fission'). It was released in English in 1966 with the title Otto Hahn: A Scientific Autobiography, with an introduction by Glenn Seaborg. The success of this book may have prompted him to write another, fuller autobiography, Otto Hahn. Mein Leben, but before it could be published, he fractured one of the vertebrae in his neck while getting out of a car. He gradually became weaker and died in Göttingen on 28 July 1968. His wife Edith survived him by only a fortnight. He was buried in the Stadtfriedhof in Göttingen. The day after his death, the Max Planck Society published the following obituary notice:
=== Acute pain === The beak is a complex, functional organ with an extensive nervous supply including nociceptors that sense pain and noxious stimuli. These would almost certainly be stimulated during beak trimming, indicating strongly that acute pain would be experienced. Behavioural evidence of pain after beak trimming in layer hen chicks has been based on the observed reduction in pecking behavior, reduced activity and social behavior, and increased sleep duration. In Japanese quail, beak-trimming by cauterization caused lower body weights and feed intake in the period just after beak trimming. Beak trimmed Muscovy ducks spent less time engaging in beak-related behaviours (preening, feeding, drinking, exploratory pecking) and more time resting than non-trimmed ducks in the days immediately post-trim. These differences disappeared by 1 week post-trim. At 1 week post-trim the trimmed ducks weighed less than non-trimmed ducks, but this difference disappeared by 2 weeks post-trim. It is, however, unclear if the above changes in behaviour arise from pain or from a loss of sensitivity in the beak. Pecking force has been found to decrease after beak trimming in adult hens, possibly indicating that hens are protecting a painful area from further stimulation. However, pecking force did not differ between chicks with or without minor beak-trims at 2 to 9 days of age, suggesting that chicks with minor beak-trims do not experience pain from the beak.
captions: A) The cetaceum (podium of cetaceans), in the Comparative Anatomy gallery B) Statue of Bernardin de Saint-Pierre, with Paul and Virginia C) The alpine garden D) The Hôtel de Magny E) The gallery of Palaeontology and Comparative Anatomy, with the statue of the First Artist by Paul Richer F) The Gallery of Mineralogy and Geology G) The greenhouse of New Caledonia built between 1834 and 1836 (at the time the "oriental pavilion") according to the plans of Charles Rohault de Fleury H) Cuvier's house on the left and the triangular pediment of the east wing of the Whale Pavilion on the right I) The Becquerel alley, north side, leads to Cuvier's house where Henri Becquerel discovered radioactivity in 1896 J) The Palaeontology gallery, on the second floor, with its mezzanine. The second floor exhibits the vertebrate fossils and the mezzanine the invertebrate fossils K) One of the zoological shelters of the menagerie L The façade of the Musée de l'Homme, in the southwest wing of the Palais de Chaillot M The botanical museum of La Jaÿsinia, in the Alps N The excavations of the Pataud shelter, in Dordogne.
Cell membranes contain a variety of biological molecules, notably lipids and proteins. Composition is not set, but constantly changing for fluidity and changes in the environment, even fluctuating during different stages of cell development. Specifically, the amount of cholesterol in human primary neuron cell membrane changes, and this change in composition affects fluidity throughout development stages. Material is incorporated into the membrane, or deleted from it, by a variety of mechanisms:
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.